Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  International Immunology

• Publication date

  1996-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/INTIMM/8.5.773PMID 8671666
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

  1996cited by this paper
• Crucial role of the pre-T-cell receptor alpha gene in development of alpha beta but not gamma delta T cells.

  1995cited by this paper
• CD3 epsilon-mediated signals rescue the development of CD4+CD8+ thymocytes in RAG-2-/- mice in the absence of TCR beta chain expression.

  1994cited by this paper
• CD3ε-mediated signals rescue the development of CD4+CD8+ thymocytes in RAG-2−/− mice in the absence of TCR β chain expression

  1994cited by this paper
• Positive selection of lymphocytes.

  1994cited by this paper
• Negative selection of lymphocytes.

  1994cited by this paper
• Onset of TCR-beta gene rearrangement and role of TCR-beta expression during CD3-CD4-CD8- thymocyte differentiation.

  1994cited by this paper
• Analysis and expression of a cloned pre-T cell receptor gene.

  1994cited by this paper
• Functional and phenotypic analysis of thymocytes in SCID mice. Evidence for functional response transitions before and after the SCID arrest point.

  1993cited by this paper
• T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases.

  1993cited by this paper
• Restoration of T cell development in RAG-2-deficient mice by functional TCR transgenes.

  1993cited by this paper
• A novel disulfide-linked heterodimer on pre—T cells consists of the T cell receptor β chain and a 33 kd glycoprotein

  1993cited by this paper
• A novel disulfide-linked heterodimer on pre-T cells consists of the T cell receptor beta chain and a 33 kd glycoprotein.

  1993cited by this paper
• A developmental pathway involving four phenotypically and functionally distinct subsets of CD3-CD4-CD8- triple-negative adult mouse thymocytes defined by CD44 and CD25 expression.

  1993cited by this paper
• Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages.

  1992cited by this paper
• Mutations in T-cell antigen receptor genes α and β block thymocyte development at different stages

  1992cited by this paper
• RAG-1-deficient mice have no mature B and T lymphocytes.

  1992cited by this paper
• RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement.

  1992cited by this paper
• Phenotypic and functional characterization of c-kit expression during intrathymic T cell development.

  1992cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper
• Phenotype, ontogeny, and repertoire of CD4-CD8- T cell receptor alpha beta + thymocytes. Variable influence of self-antigens on T cell receptor V beta usage.

  1991cited by this paper
• In vivo administration of monoclonal antibodies to the CD3 T cell receptor complex induces cell death (apoptosis) in immature thymocytes.

  1991cited by this paper
• Cytokines in T-cell development.

  1991cited by this paper
• Developmental biology of T cells in T cell-receptor transgenic mice.

  1990cited by this paper
• NK1.1+ thymocytes. Adult murine CD4-, CD8- thymocytes contain an NK1.1+, CD3+, CD5hi, CD44hi, TCR-V beta 8+ subset.

  1990cited by this paper
• Ontogeny of a novel CD4+CD8-CD3- thymocyte subpopulation: a comparison with CD4- CD8+ CD3- thymocytes.

  1990cited by this paper
• Developmental biology of T cells in T cell-receptor transgenic mice.

  1990cited by this paper
• A murine early thymocyte developmental sequence is marked by transient expression of the interleukin 2 receptor.

  1989cited by this paper
• Monoclonal antibodies specific to native murine T-cell receptor gamma delta: analysis of gamma delta T cells during thymic ontogeny and in peripheral lymphoid organs.

  1989cited by this paper
• Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors

  1988cited by this paper
• Identification of a monoclonal antibody specific for a murine T3 polypeptide.

  1987cited by this paper
• Early events in T-cell maturation.

  1987cited by this paper
• Establishment of Monoclonal Anti-Nk-1.1 Antibody

  1984cited by this paper

• Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

  2026cites this paper
• Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.

  2025cites this paper
• Exosomal PD-L1 in non-small cell lung Cancer: Implications for immune evasion and resistance to immunotherapy.

  2025cites this paper
• Immune Checkpoint Inhibitors (ICI) in Urological Cancers: A New Modern Era, but Not Generally Applied

  2025cites this paper
• Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype

  2025cites this paper
• DETECTION OF HUMAN PD-1 ON T-CELLS USING A FUSION PROTEIN CONSISTING OF AN ANTI-PD-1 SINGLE CHAIN VARIABLE FRAGMENT LINKED TO SUPERFOLDER GFP.

  2025cites this paper
• Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: The Clinical Impact of Immune Checkpoint Inhibitors—A Systematic Review

  2025cites this paper
• 3-in-one PD-1CAR Tregs: A bioengineered cellular therapy for target engagement, activation, and immunosuppression with reparative potential

  2025cites this paper
• Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications

  2025cites this paper
• Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis

  2025cites this paper
• Genetic variants in PD-1 and its ligands, gene-gene and gene-environment interactions in allergic rhinitis.

  2025cites this paper
• Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates

  2025cites this paper
• Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option

  2025cites this paper
• Small-molecule modulators of tumor immune microenvironment.

  2024cites this paper
• PD-1 Limits IL-2 Production and Thymic Regulatory T Cell Development

  2024cites this paper
• Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies

  2024cites this paper
• Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

  2024cites this paper
• Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

  2024cites this paper
• PD-1 regulation in immune homeostasis and immunotherapy.

  2024cites this paper
• The PD-1 and PD-L1 checkpoint and the application of their inhibitors

  2024cites this paper
• Serum Concentrations of TIM-3, LAG-3, and PD-1 in Patients with Hemorrhagic Fever with Renal Syndrome

  2024cites this paper
• Early allogeneic immune modulation after establishment of donor hematopoietic cell-induced mixed chimerism in a nonhuman primate kidney transplant model

  2024cites this paper
• Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment.

  2024cites this paper
• PD-L1 peptides in cancer immunoimaging and immunotherapy.

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• The PD-1–PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration

  2024cites this paper
• cAMP responsive element modulator α promotes effector T cells in systemic autoimmune diseases

  2023cites this paper
• Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1.

  2023cites this paper
• PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic Hodgkin lymphoma

  2023cites this paper
• Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma

  2023cites this paper
• A binary module for microbiota-mediated regulation of γδ17 cells, hallmarked by microbiota-driven expression of programmed cell death protein 1

  2023cites this paper
• Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies.

  2023cites this paper
• The usage of Pembrolizumab in Metastatic Urothelial Carcinoma

  2023cites this paper
• Cumulative effects of weakly repressive regulatory regions in the 3’ UTR maintain PD-1 expression homeostasis in mammals

  2023cites this paper
• Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.

  2023cites this paper
• Establishment of CD8+ T cell thymic central tolerance to tissue-restricted antigen requires PD-1

  2023cites this paper
• Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation

  2022cites this paper
• The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.

  2022cites this paper
• Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis

  2022cites this paper
• Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that INHIBITS the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells.

  2022cites this paper
• Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma

  2022cites this paper
• Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.

  2022cites this paper
• Immunogenetics of Lupus Erythematosus.

  2022cites this paper
• Lentivirus-mediated PD-L1 overexpression in bone marrow-derived dendritic cells induces immune tolerance in a rat keratoplasty model.

  2022cites this paper
• Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4

  2021cites this paper
• [Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology].

  2021cites this paper
• Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.

  2021cites this paper
• LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients

  2021cites this paper
• Dampening antiviral immunity can protect the host

  2021cites this paper
• Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade

  2021cites this paper
• Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer

  2021cites this paper
• Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells

  2021cites this paper
• YY1 expression and PD-1 regulation in CD8 T lymphocytes

  2021cites this paper
• Metabolic barriers to cancer immunotherapy

  2021cites this paper
• The PD-1 Interactome

  2021cites this paper
• A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer

  2021cites this paper
• The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.

  2021cites this paper
• Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.

  2021cites this paper
• The role of complement in the tumor microenvironment

  2021cites this paper
• Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications

  2021cites this paper
• Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy

  2021cites this paper
• Mitochondria Determine Response to Anti-programmed Cell Death Protein 1 (Anti-PD-1) Immunotherapy: An Evidence-based Hypothesis.

  2021cites this paper
• Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective.

  2021cites this paper
• Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.

  2021cites this paper
• The role of exosomal PD-L1 in tumor immunotherapy

  2021cites this paper
• An Updated Understanding of the Role of YAP in Driving Oncogenic Responses

  2021cites this paper
• Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases

  2021cites this paper
• The Role of Innate Lymphoid Cells in the Regulation of Immune Homeostasis in Sepsis-Mediated Lung Inflammation

  2020cites this paper
• Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms

  2020cites this paper
• Mitochondria Determine Response to Anti-PD-1 Therapy: An Evidence-based Hypothesis

  2020cites this paper
• Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

  2020cites this paper
• The Stone Guest: How Does pH Affect Binding Properties of PD‐1/PD‐L1 Inhibitors?

  2020cites this paper
• Gastrointestinal cancers: current biomarkers in esophageal and gastric adenocarcinoma.

  2020cites this paper
• CCL22 Signaling in the Tumor Environment.

  2020cites this paper
• Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod‑treated mice.

  2020cites this paper
• CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions

  2020cites this paper
• An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells

  2020cites this paper
• Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.

  2020cites this paper
• Regulation of PD-1 in T cells for cancer immunotherapy.

  2020cites this paper
• Immune-Checkpoint Inhibitors in B-Cell Lymphoma

  2020cites this paper
• KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression

  2020cites this paper
• Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo

  2019cites this paper
• Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

  2019cites this paper
• PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease

  2019cites this paper
• Targeting Programmed Cell Death ‐1 (PD‐1) and Ligand (PD‐L1): A new era in cancer active immunotherapy

  2019cites this paper
• Programmed cell death protein receptor and ligands in haematological malignancies - Current status.

  2019cites this paper
• Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines.

  2019cites this paper
• Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice

  2019cites this paper
• Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma

  2019cites this paper
• Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer.

  2019cites this paper
• The Emerging Role of YAP/TAZ in Tumor Immunity

  2019cites this paper
• Recent advances in the clinical development of immune checkpoint blockade therapy

  2019cites this paper
• Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles

  2019cites this paper
• University of Groningen Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles Guzik,

  2019cites this paper
• L 1 w chorobach nowotworowych Monoclonal antibodies against PD-1 / PD-L 1 pathway

  2019cites this paper
• Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia

  2019cites this paper
• Control of Regulatory T Cells by Co-signal Molecules.

  2019cites this paper
• Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.

  2018cites this paper